Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued on Tuesday. The firm set a "hold" rating on the medical research company's stock.

Several other equities analysts also recently weighed in on CTSO. D. Boral Capital reissued a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a research report on Friday, May 2nd. HC Wainwright reiterated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a report on Thursday, April 3rd.

Cytosorbents Price Performance

CTSO traded up $0.07 during trading on Tuesday, reaching $0.90. 162,973 shares of the stock were exchanged, compared to its average volume of 146,936. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The company has a market capitalization of $56.35 million, a price-to-earnings ratio of -2.50 and a beta of 1.17. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61. The business's 50 day moving average price is $1.00 and its two-hundred day moving average price is $0.99.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.01 million. As a group, equities research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. Skylands Capital LLC raised its holdings in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after purchasing an additional 26,195 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents during the 4th quarter valued at about $99,000. Renaissance Technologies LLC lifted its position in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares in the last quarter. Avenir Corp boosted its stake in shares of Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Finally, Northern Trust Corp increased its stake in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.